Cell Culture Services — Design → GMP, without detours

Scope: Mammalian (CHO/HEK & hybridoma), Insect (BEVS), adherent on microcarriers, and suspension platforms—underpinned by microbial fermentation expertise that keeps upstream assumptions honest and scale-behavior predictable. Time to learn about our cell culture services…

MycoVista’s cell culture services are engineered around a simple rule: manufacturability by default. From vector to vial, every decision traces to a Critical Quality Attribute (CQA), an assay with system suitability, and a documented, version-controlled method. We architect processes with QTPP→CQA→CPP mapping, then confirm true drivers via focused DoE and edge-of-failure studies to lock NOR/PAR and establish defensible ranges before PPQ. For mammalian systems, we tune glycan and charge windows through feed, temperature, and residence-time control; for BEVS, we harmonize MOI, infection timing, and harvest criteria to stabilize productivity and quality lot-to-lot. Adherent lines transition to suspension or microcarrier perfusion with defined kLa, shear envelopes, and retention guardbands; filtration/lyo feasibility is proven early to prevent downstream surprises.

Downstream is sized on real harvests—Protein A or alternatives, IEX/HIC/mixed-mode polishing, viral filtration, and UF/DF—with mass balance and impurity clearance trended each run. Analytics is our OS: SEC-MALS, CE-SDS, icIEF, glycan profiling, potency, and EM where relevant, all linked to ALCOA+ digital records (eBMR/eBR, LIMS/ELN, CPV). The outcome is a platform-agnostic backbone where it accelerates speed and comparability, and bespoke controls where your biology demands it.

Choose MycoVista’s cell culture services for fewer handoffs, fewer unknowns, and faster learning loops—delivering inspection-grade outputs at every gate. As a biopharmaceutical CDMO, our integrated upstream–downstream–analytics alignment ensures your program scales cleanly. When cell culture services must move from Design → Data → Decision → GMP, we make the operating reality match the dossier.

Why teams choose MycoVista for cell culture

Decisive. Technical. Audit-ready. That’s our operating system.

• End-to-end ownership. Cell line development → upstream PD (batch, fed-batch, perfusion) → downstream compatibility → analytics → fill–finish, harmonized across two synchronized facilities and a unified digital QMS (ALCOA+).
• Depth in the hard parts. High-productivity CLD with documented clonality; high-seed fed-batch and perfusion intensification; microcarrier perfusion for adherent lines; insect expression when timeline wins; refold-aware purification schemes carried upstream in the design.
• Analytics first. Real process truths come from data. We design DoE with PAT from day one and make decisions on evidence—not optimism.
• Microbial fermentation synergy. Our microbial group (E. coli, Pichia, Bacillus, Corynebacterium) informs mammalian risk controls for oxygen transfer, mass balance, and resin/filtration loading limits. Cross-modal thinking prevents surprises at scale.

What “Cell Culture” means at MycoVista

• Mammalian—CHO/HEK & hybridoma (mAbs, enzymes, Fc-fusions, bispecifics): High-productivity, stable cell lines with predictable glycan profiles, built for perfusion or intensified fed-batch.
• Adherent → Suspension: Microcarrier perfusion for true anchorage-dependent lines; serum-free adaptation and suspension conversion where feasible.
• Insect—BEVS (Sf9/Sf21/High Five): Fast recombinant protein expression for subunit vaccines, IVD reagents, and therapeutics research through clinical supply.
• Process bridges into DSP: Protein A or alternative capture, polishing (IEX/HIC/MM), viral inactivation/filtration, UF/DF—planned jointly from the first upstream experiment.
• Regulatory & scale intent from day one: IND/IMPD language, method qualification/validation plans, and stability strategy are built into development—not bolted on.

Advanced Cell Line Development (CLD)

Goal: A line that makes your molecule the way you need to release it—at a titer and quality that scale.

Vector strategy, host selection, and integration

• Hosts: CHO (GS/DHFR lineages), HEK for certain glyco-sensitive or complex proteins, hybridoma for classical mAb workflows.
• Integration strategies: targeted knock-ins, site-preferred recombinase systems, transposon-based diversification—chosen to balance copy number, stability, and quality.
• Selection systems: GS, DHFR, or dual-marker strategies tuned for product-specific expression and metabolic load.
• Expression tuning: promoter/UTR architecture, signal peptides for secretion, isotype/hinge for mAbs and Fc-fusions, and codon optimization with manufacturability heuristics (disulfide load, PTM liabilities, predicted aggregation).

From pool to clone to bank

• High-throughput pool screening under process-relevant conditions (feed, temperature, osmolality) so early data actually predicts scale.
• Single-cell cloning (e.g., FACS or imaging-confirmed limiting dilution) with clonality documentation (images and metadata) stitched straight into the QMS.
• Productivity + quality triage: titer, specific productivity (qP), product quality (glycan profile, charge variants, HCP/DNA carryover risk) and manufacturability signals (shear, foam, filtration behavior).
• Stability studies across passages and process conditions so your MCB/WCB doesn’t surprise you three campaigns later.

“Manufacturability” gates

• Glycan comparability windows defined early; afucosylation/sialylation control strategies if potency depends on it.
• Clip, deamidation, glycation, oxidation tracked in CLD—not discovered at PPQ.
• Purification reality checks: capture loading limits, polishing selectivity, viral inactivation compatibility, and UF/DF behavior measured on real harvest, not just buffer spikes.

Banking and release (MCB/WCB)

• MCB/WCB under cGMP controls, with mycoplasma/adventitious agent testing, identity/sequence confirmation, and stability program enrollment.
• Global readiness: banking packages aligned to U.S./EU expectations; bilingual (EN/FR) documentation available.

Upstream Process Development (USP): batch, fed-batch, perfusion—by design

We design the process to meet your control strategy, not the other way around.

Feeding architectures and intensification

• Fed-batch classics—done right: optimized feed profiles, temperature/ORP/osmolality shaping, anti-stress strategies for high-titer runs.
• High-seed fed-batch & N-1 perfusion: shortened cycle times, higher peak cell densities, and more predictable CPP/CQA control.
• True perfusion: where residence time and product quality demand it—cell retention and bleed strategies picked for robustness and cleaning validation compatibility.

Microcarrier perfusion for adherent lines

• When suspension isn’t an option: we lean on decades of microcarrier perfusion experience to reach high viable cell densities with tight fouling and shear control.
• Outcome: long-run stability without the roller-bottle labor tax, and harvests that integrate with modern DSP.

Bioreactor execution & control

• Seed trains designed for metabolic consistency and rapid turnaround.
• Control loops for pH/DO/CO₂, antifoam, and feed interlocks; oxygen transfer (kLa) engineering that respects real viscosity and gas limits.
• Shear management (impeller selection, tip speed, sparger strategy) matched to cell sensitivity, not a spec sheet.
• Scalable analytics: at-line titer, metabolites (glucose, lactate, ammonia), and viability to keep runs “decisionable” daily.

Process Analytical Technology (PAT)

• Spectroscopic monitoring (e.g., Raman/capacitance) and soft sensors to track biomass, metabolites, and CPPs—validated against reference analytics.
• Data models that predict drift and trigger corrective actions before deviations stack up.
• Design space formalized via DoE; we publish ranges and interactions, not just best-day points.

Downstream starts upstream

Even on a “Cell Culture” page, we talk purification—because upstream without DSP reality isn’t development.

• Capture: Protein A or modality-appropriate alternatives—loading limits and breakthrough behaviors measured on process harvests.
• Polishing: ion exchange (IEX), hydrophobic interaction (HIC), mixed-mode (MM)—selected by real impurity maps (HCP, fragments, charge variants).
• Viral safety: low-pH inactivation compatibility confirmed during USP scouting; viral filtration pressure/throughput designed to avoid hockey sticks at PPQ.
• UF/DF: stage-wise concentration/diafiltration planning with aggregation/leakage thresholds that match your release.

Analytics and characterization: decisions come from data

• Identity & purity: intact mass, peptide mapping, CE-SDS (R/NR), icIEF; SEC-MALS for size variants; glycan profiling (release and, where useful, site-specific).
• Potency & binding: cell-based assays, Fc-effector (ADCC/CDC), binding kinetics.
• Process residuals: HCP, host cell DNA, Protein A residual; endotoxin/bioburden/sterility; mycoplasma.
• Stability: real-time and accelerated with conditions that reflect your shipping and storage intent; stress studies that inform formulation.

Insect cell culture (BEVS): timeline wins, quality holds

When speed to material is paramount—or when mammalian post-translational needs are modest—BEVS shines.

• Vectors: genes under polyhedrin control in AcNPV-based systems.
• Cells: Sf9/Sf21 for expansion; High Five for yield/quality balance.
• Scale: from shake to production, with purification and analytics folded in from the first expression test.
• Use cases: sub-unit vaccine antigens, IVD raw materials, discovery-to-clinic recombinant proteins.

Adherent programs: microcarriers that actually scale

Anchorage-dependent lines don’t need to mean slow, fragile, or unscalable.

• Perfusion microcarrier systems tuned for shear, oxygen, and fouling; year-scale operational experience.
• Serum-free adaptation where biology allows; microcarrier selection by cell affinity and process hydrodynamics.
• Harvest plans that deliver to DSP without turning recovery into an R&D experiment.

Microbial fermentation synergy

Our microbial team’s instincts for oxygen transfer, carbon balance, and mass flux keep mammalian assumptions honest.

• kLa realism borrowed from high-density fermentation means we design mammalian O₂ strategies with headroom.
• Resin loading discipline learned on microbial enzymes protects capture steps from false economies.
• Team structure: mammalian and microbial PD leads share a control-strategy template to avoid “two truths” in a single CMC.

Facilities & scale

• Mammalian single-use bioreactors: 50 L and 250 L suites validated for GMP; benchtop through multi-thousand-liter perfusion footprints for late-stage/registration-intent programs.
• Insect expansion & production with dedicated containment and workflows.
• Microbial & fungal: bench → pilot → up to 50,000 L stainless for qualified projects.
• Cleanrooms: ISO 8/7, positive pressure, HEPA, unidirectional flows; BSL-2 where required.
• Support suites: media/solution prep, sterilization, analytical (metabolites, protein), HPLC, PCR/ELISA, electrophoresis; LN₂ cell storage; vacuum autoclave; dry-heat depyrogenation.
• Materials: critical reagents sourced from audited suppliers (U.S., New Zealand, Australia); traceability documented.

cGMP, regulatory, and QMS

• QbD: QTPP → CQA → CPP mapped at project start; risk-based DoE locked in protocols.
• Digital QMS (ALCOA+): eBMR/eBR, deviation/CAPA, change control, validated computerized systems—harmonized across San Diego & Montréal with mirrored methods and release packages.
• Regulatory: IND/IMPD authoring support; method qualification/validation plans; PPQ road-mapping; ICH-aligned stability.
• Documentation: clonality proof packs, assay method files, batch records, and CoAs/CoCs that survive real audits.

Program Onboarding (the first 30 days)

Speed is useful only if outputs are inspection-grade. In month one you receive:

1. A phase-appropriate QTPP and draft control strategy that link CQAs to inputs and parameters.
2. A DoE plan for USP/DSP and analytics, with sampling plans and pass/fail criteria.
3. A Gantt and risk map (FMEA) with decision gates to IND/registration—plus a proposed stability plan and a banking timeline.

Start: Share payload class, route, dose goals, desired scale, and stability targets. We return a design space, analytics, mixing/aeration and perfusion parameters, fill–finish options, and a documented path to GMP.

Typical timelines (indicative, not promises)

• CLD to MCB (mammalian): pool → clone with documented clonality → engineering runs → banking with release testing—timelines gated by biology, not wishful thinking.
• USP PD: screens, DoE, pre-scale runs, and process lock when CPPs and CQAs land in defined windows.
• BEVS: gene to material at program speeds that keep your milestones intact—analytics and purification co-developed.
• Adherent to suspension: where feasible; otherwise microcarrier perfusion with validated harvest.

Tech transfer & rescue programs

We take over projects mid-flight, stabilize them, and get them moving.

• Document triage: methods, deviations, analytics, stability, and change control history.
• Gap mapping: where data lacks, where risks live, and what to do first (not everything at once).
• Stabilize → optimize → re-lock: we don’t ship risk; we document it, reduce it, and gate it.

ESG and supply chain

• Sane single-use strategy: disposables where they cut risk and time; stainless where they cut cost and waste.
• Supply chain: qualified alternates for critical feeds, resins, filters, and plastics; stocking levels that match campaign risk.
• Energy & water awareness and closed-system design where bioburden control and utilities stability benefit most.

What you actually get (deliverables you can hold)

• Clonality dossier with images/metadata and stability evidence.
• Process description with design space and CPP limits; validated control loops and interlocks.
• Analytics package with methods, qualification/validation status, and trending.
• Banking and release documents (MCB/WCB) with testing and storage details.
• Stability protocol and interim data; IND/IMPD language for CMC sections.
• Run records (eBMR/eBR) that tie each decision to a datum.

A few patterns that make us different

• Manufacturability by default: we won’t push a condition that breaks capture just to win a titer headline.
• “One truth” rule: the same control strategy follows your molecule across sites and scales.
• Daily decisionality: we design runs so you can make a same-day call from the data room.
• No brand worship: we choose tools that serve your biology and your audit, not our marketing.

FAQ

Can you adapt our adherent line to suspension?

Often yes. If not, we deploy microcarrier perfusion—the point is manufacturability, not ideology.

Perfusion or fed-batch?

We model both. If quality or timeline needs perfusion, we build it. If fed-batch meets targets with less complexity, we ship the simpler truth.

Do you support BEVS for clinical material?

Yes—research to clinical supply with appropriate analytics and purification; we’ll tell you where the platform fits and where mammalian is required.

What scales do you run?

Mammalian single-use 50 L/250 L GMP suites with benchtop and multi-thousand-liter perfusion footprints; microbial/fungal to 50,000 L for combo or adjacent programs.

Regulatory posture?

IND/IMPD/BLA-aligned artifacts, unified QMS (ALCOA+), audits welcomed.

Summary—why MycoVista for cell culture

Because you don’t need another service list. You need a partner that turns biology into a controlled, scalable, inspectable process. We design with the end in mind—Design → Data → Decision—and we carry that through CLD, USP, DSP, analytics, banks, stability, and the documents that keep regulators comfortable and milestones real.

MycoVista | San Diego, CA

Start Program Onboarding → Share payload class, route, dose goals, scale, and stability targets. We’ll return a design space, control strategy, and a documented path to GMP.

Email our team today at info@mycovistabiotech.com